SOUTH SAN FRANCISCO, Calif.,
Oct. 29, 2020 /PRNewswire/
-- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today
announced that it will report its third quarter 2020 financial
results after market close on Thursday,
November 5, 2020. Rigel senior management will follow
the announcement with a live conference call and webcast at
4:30pm Eastern Time (1:30pm Pacific Time) to discuss the financial
results and give an update on the business.
Participants can access the live conference call by dialing
1-800-954-0603 (domestic) or 1-415-226-5355 (international).
The conference call and accompanying slides will also be webcast
live and can be accessed from the Investor Relations section of the
company's website at www.rigel.com. The webcast will be
archived and available for replay for 90 days after the call via
the Rigel website.
About Rigel (www.rigel.com)
Rigel Pharmaceuticals,
Inc. is a biotechnology company dedicated to discovering,
developing and providing novel small molecule drugs that
significantly improve the lives of patients with immune and
hematologic disorders, cancer and rare diseases. Rigel's pioneering
research focuses on signaling pathways that are critical to disease
mechanisms. The company's first FDA approved product is
TAVALISSE® (fostamatinib disodium hexahydrate) tablets,
the only oral spleen tyrosine kinase (SYK) inhibitor, for the
treatment of adult patients with chronic immune thrombocytopenia
who have had an insufficient response to a previous treatment. The
product has been approved by the European Commission for the
treatment of chronic immune thrombocytopenia in adult patients who
are refractory to other treatments and is marketed in Europe under the name TAVLESSE®
(fostamatinib).
Fostamatinib1 is currently being studied in a Phase 3
trial for the treatment of warm autoimmune hemolytic anemia (AIHA);
a NIH/NHLBI-Sponsored Phase 2 trial for the treatment of
hospitalized COVID-19 patients, in collaboration with Inova® Health
System; and a Phase 2 trial for the treatment of COVID-19 pneumonia
being conducted by Imperial College London.
Rigel's other clinical programs include an ongoing Phase 1 study
of R8351, a proprietary molecule from its interleukin
receptor associated kinase (IRAK) inhibitor program, and an ongoing
Phase 1 study of R5521, a proprietary molecule from its
receptor-interacting protein kinase (RIP) inhibitor program. In
addition, Rigel has product candidates in clinical development with
partners AstraZeneca, BerGenBio ASA, and Daiichi Sankyo.
Please see www.TAVALISSE.com for the full Prescribing
Information.
1The product for this use or indication is
investigational and has not been proven safe or effective by any
regulatory authority.
Contact: David Burke
Phone: 650.624.1232
Email: dburke@rigel.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/rigel-announces-conference-call-and-webcast-to-report-third-quarter-2020-financial-results-and-business-update-301162491.html
SOURCE Rigel Pharmaceuticals, Inc.